[^1]
[^2]
[^1]
[^3]
[^1]
[^2]
[^4]
[^5]
[^6]
| FRDA1 Gene |
|---|
| Official Symbol | FXN |
| Previous Symbol | FRDA |
| Full Name | Frataxin |
| Chromosomal Location | 9q21.11 |
| NCBI Gene ID | [2395](https://www.ncbi.nlm.nih.gov/gene/2395) |
| OMIM | [229300](https://www.omim.org/entry/229300) |
| UniProt ID | [Q16595](https://www.uniprot.org/uniprotkb/Q16595/entry) |
| Protein Category | Mitochondrial Protein |
The FRDA1 gene (officially symbol FXN) encodes frataxin, a small mitochondrial protein that plays a critical role in iron-sulfur cluster (Fe-S) biogenesis and mitochondrial iron homeostasis . Frataxin is essential for the assembly of Fe-S clusters, which serve as essential cofactors for numerous enzymes involved in oxidative phosphorylation, electron transport, and DNA repair. The discovery that GAA repeat expansions in the first intron of FXN cause Friedreich ataxia (FA) has made this gene a central focus of neurodegenerative disease research .
Friedreich ataxia is an autosomal recessive neurodegenerative disorder characterized by progressive ataxia, cardiomyopathy, diabetes mellitus, and loss of sensory function. The disease typically presents in childhood and leads to severe disability, with most patients becoming wheelchair-bound by their early twenties . Understanding frataxin function has provided critical insights into mitochondrial dysfunction in neurodegeneration and has informed therapeutic development efforts.
Frataxin serves as the core scaffold protein for mitochondrial Fe-S cluster assembly :
-
Iron donation:
- Frataxin binds ferrous iron (Fe²⁺) with high affinity
- Forms a iron-loaded oligomeric complex
- Provides iron for cluster assembly on scaffold proteins
-
Cluster assembly:
- Cooperates with ISCU (iron-sulfur cluster scaffold)
- Facilitates sulfur transfer from NFS1
- Enables rapid cluster formation and transfer
-
Cluster transfer:
- Delivers assembled clusters to target proteins
- Supports multiple Fe-S enzyme maturation
- Requires interaction with ferredoxin
Frataxin plays a crucial role in regulating mitochondrial iron levels :
- Iron import regulation: Controls mitochondrial iron uptake through MIYAML
- Iron storage coordination: Works with mitochondrial ferritin (FTMT)
- Prevents iron overload: Avoids toxic Fenton chemistry
- Protects against ferroptosis: Mitochondrial iron-mediated cell death
FXN is ubiquitously expressed with highest levels in:
- Heart: Highest expression - explains cardiac involvement
- Liver: High metabolic demand
- Kidney: Energy-intensive transport
- Brain: Dorsal root ganglia, cerebellum, spinal cord
- Skeletal muscle: High mitochondrial content
Within the nervous system:
¶ Structure and Biochemistry
Frataxin is a 210-amino acid protein with distinct domains :
- N-terminal mitochondrial targeting sequence (1-40 aa)
- Alpha-helical domain (41-90 aa) - protein interactions
- Beta-sheet core (91-155 aa) - iron binding
- C-terminal region (156-210 aa) - oligomerization
The protein forms a banana-shaped dimer that can further oligomerize in the presence of iron.
- Binding sites: Multiple surface-exposed acidic residues
- Iron capacity: Up to 12 iron atoms per monomer
- Cooperativity: Iron binding shows positive cooperativity
- Dissociation constant: ~10⁻⁶ M for Fe²⁺
- Iron-dependent assembly: Iron promotes higher-order oligomers
- Functional oligomers: Form larger complexes in vivo
- Phase separation: May form membrane-less organelles for cluster assembly
| Feature |
Description |
| Inheritance |
Autosomal recessive |
| Prevalence |
1:50,000-1:40,000 |
| Onset |
Childhood (5-15 years) |
| Core Symptoms |
Ataxia, dysarthria, loss of proprioception |
| Additional Features |
Cardiomyopathy, diabetes mellitus |
| GAA Repeat |
66-1700 repeats in intron 1 |
The GAA repeat expansion in FXN intron 1 causes:
-
Reduced transcription:
- Forms triple-helix DNA structure
- Inhibits transcription elongation
- Reduces frataxin protein to 5-30% of normal
-
Mitochondrial dysfunction:
- Impaired Fe-S cluster assembly
- Reduced oxidative phosphorylation
- Energy deficit in high-demand tissues
-
Iron dysregulation:
- Mitochondrial iron accumulation
- Oxidative stress from Fenton chemistry
- Cellular toxicity
-
Neurodegeneration:
- Dorsal root ganglion degeneration
- Spinocerebellar tract damage
- Cardiomyocyte loss
Frataxin deficiency causes severe cardiac involvement :
- Hypertrophic cardiomyopathy: Most common
- Dilated cardiomyopathy: In later stages
- Heart failure: Leading cause of mortality
- Arrhythmias: Including atrial fibrillation
- Sudden cardiac death: Risk in advanced disease
Approximately 10-30% of FA patients develop diabetes :
- Mechanism: Pancreatic beta-cell dysfunction
- Correlation: Frataxin deficiency in pancreas
- Treatment: Insulin therapy often required
- Screening: Regular glucose monitoring essential
While FA is the primary disease, frataxin dysfunction may contribute to:
-
Alzheimer's disease:
- Reduced frataxin in AD brain
- Mitochondrial dysfunction in AD neurons
- Iron dysregulation in AD
-
Parkinson's disease:
- Frataxin in dopaminergic neurons
- Mitochondrial vulnerability
- Iron accumulation in substantia nigra
-
Amyotrophic lateral sclerosis:
- Mitochondrial dysfunction in motor neurons
- Energy deficit
- Oxidative stress
The mitochondrial Fe-S cluster assembly (ISC) machinery includes :
- Iron import: Mitoferrin-1/2 (SLC25A37/38)
- Sulfur mobilization: NFS1, ISD11
- Scaffold protein: ISCU (iron-sulfur cluster scaffold)
- Electron transfer: Ferredoxin (FDX1/2)
- Chaperones: HSPA9, HSC20
- Core protein: Frataxin (FXN)
- Frataxin deficiency → Impaired Fe-S assembly
- Fe-S enzyme dysfunction → Respiratory chain defects
- ATP depletion → Energy failure
- Iron accumulation → Oxidative stress
- Cellular death → Tissue degeneration
Frataxin deficiency leads to oxidative damage :
- Complex I deficiency: NADH:ubiquinone oxidoreductase
- Complex II deficiency: Succinate:ubiquinone oxidoreductase
- Aconitase inactivation: Iron-sulfur enzyme
- DNA damage: 8-oxoguanine accumulation
- Reduced ATP: 30-70% decrease in affected tissues
- Impaired glucose metabolism: Insulin resistance
- Fatty acid oxidation: Reduced beta-oxidation
- Apoptosis susceptibility: Increased cell death
¶ Current and Emerging Therapies
| Approach |
Description |
Status |
| Gene therapy |
AAV-mediated FXN delivery |
Phase I/II trials |
| RNAi silencing |
Reduce toxic repeat transcripts |
Preclinical |
| Iron chelation |
Deferoxamine, deferasirox |
Clinical trials |
| Antioxidants |
CoQ10, idebenone |
Approved in Europe |
| HDAC inhibitors |
Increase frataxin expression |
Clinical trials |
| Mitochondrial protectors |
Pioglitazone |
Phase II |
AAV vectors delivering functional FXN are in development :
- Vectors: AAV9, AAVrh.10
- Delivery: Systemic, intracardiac, or intrathecal
- Dosing: Dose-escalation studies
- Endpoints: Safety and biomarkers
- Challenge: Achieving sufficient expression
-
Frataxin expression enhancers:
- HDAC inhibitors (vorinostat, panobinostat)
- Erythropoietin derivatives
- Bithionol
-
Mitochondrial function:
- Coenzyme Q10 + L-carnitine
- Idebenone (approved in Europe)
- Mitochondrial peptides
-
Iron chelation:
- Deferoxamine
- Deferasirox
- ICL670
Several trials are investigating FA therapies:
- AAV-FXN gene therapy (NCT04162288)
- Omaveloxolone (NCT02255435) - FDA approved
- Edaravone in FA (NCT03829514)
- Bithionol (NCT02780180)
- Fxn knockout: Embryonic lethal
- Conditional knockouts: Tissue-specific deletion
- GAA knock-in: Mimics patient repeat
- Transgenic models: Human FXN expression
- fxna/fxnb morphants: Developmental defects
- Mitochondrial dysfunction
- Cardiac abnormalities
- Patient-derived fibroblasts
- iPSC neurons
- Dorsal root ganglion cultures
- Campuzano et al., Frataxin and Friedreich ataxia. Science. 1996 — Discovery of FXN as FA gene
- Puccio et al., Frataxin and mitochondrial iron homeostasis. Nat Genet. 2001 — Mitochondrial iron regulation
- Pandolfo et al., Friedreich ataxia: From disease mechanisms to therapeutic approaches. Nat Rev Neurol. 2014 — Comprehensive review
- Koeppen et al., The neuropathology of Friedreich ataxia. J Neuropathol Exp Neurol. 2018 — Pathology
- Schmucker et al., Frataxin: A mitochondrial iron-sulfur cluster assembly protein. Cell. 2008 — Structural function
- Lodi et al., Frataxin mutations and mitochondrial dysfunction. Brain. 2015 — Mitochondrial defects
- Gomez et al., Oxidative stress in Friedreich ataxia. Antioxid Redox Signal. 2014 — Oxidative mechanisms
- Marti et al., Frataxin: From function to therapy. Exp Neurol. 2019 — Therapy review
- Strawinski et al., Frataxin and cardiac involvement in Friedreich ataxia. J Am Coll Cardiol. 2018 — Cardiac aspects
- Wilson et al., Therapeutic approaches for Friedreich ataxia. J Clin Med. 2019 — Treatment strategies